{"id":"fp-025-capsules","_chembl":null,"modality":"Small molecule","_dailymed":null,"_scrapedAt":"2026-03-28T03:32:55.529Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123265,"model":"claude-sonnet-4-5-20250929"},"description":"FP-025 is an investigational oral capsule formulation being developed by Foresee Pharmaceuticals Co., Ltd. Currently in Phase 2 clinical trials, the drug's molecular target, mechanism of action, and specific therapeutic indication have not been publicly disclosed.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT03858686","phase":"PHASE2","title":"The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.","status":"COMPLETED","sponsor":"Foresee Pharmaceuticals Co., Ltd.","startDate":"2018-07-02","conditions":"Asthma, COPD","enrollment":27},{"nctId":"NCT02238834","phase":"PHASE1","title":"Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers","status":"COMPLETED","sponsor":"Foresee Pharmaceuticals Co., Ltd.","startDate":"2015-06","conditions":"Healthy","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Adermastat","Placebo"],"phase":"phase_2","status":"active","brandName":"FP-025 capsules","genericName":"FP-025 capsules","companyName":"Foresee Pharmaceuticals Co., Ltd.","companyId":"foresee-pharmaceuticals-co-ltd","firstApprovalDate":"","aiSummary":"FP-025 capsules are a small molecule intervention being studied for their effects on allergen-induced airway responses in mild eosinophilic house dust mite-allergic asthma. The capsules are being investigated in clinical trials, including one registered on ClinicalTrials.gov as NCT03858686, where they are being compared to a placebo.","enrichmentLevel":2,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}